[1] MacDONAD H, KELLY R G, ALLEN E S. Pharmacokinetic studies on minocycline in man, 1973(5)
[2] CARNEY S, BUTCHER R A, DAWBORN J K. Minocycline excretion and distribution in relation to renal function in man, 1974(4)
[3] WELLS J, HURLBERT J, FEHLINGS M. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury. 2003(7). doi:10.1093/brain/awg178
[4] TENG Y D, CHOI H, ONARIO R C. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. 2004(9). doi:10.1073/pnas.0306239101
[5] STIRLING D P, KHODARAHMI K, LIU J. Minocycline treatment reduces delayed oligodendrocyte death,attenuates axonal dieback,and improves functional outcome after spinal cord injury. 2004(9)
[6] YRJANHEIKKI J, KEINANEN R, PELLIKKA M. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. 1998(26). doi:10.1073/pnas.95.26.15769
[7] WU D C, JACKSON-LEWIS V, VILA M. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. 2002(5)
[8] POPOVIC N, SCHUBART A, GOETZ B D. Inhibition of autoimmune encephalomyelitis by a tetracycline. 2002(2). doi:10.1002/ana.10092
[9] POWER C, HENRY S, DEL BIGIO M R. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. 2003(6). doi:10.1002/ana.10553
[10] YRJANHEIKKI J, TIKKA T, KEINANEN R. A tetracycline derivative,minocycline,reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window, 1999(23)
[11] TIKKA T, FIEBICH B L, GOLDSTEINS G. Minocycline,a tetracycline derivative,is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. 2001(8)
[12] GABLER W L, SMITH J, TSUKUDA N. Comparison of deoxycycline and a chemically modified tetracycline inhibition of leukocyte functions, 1992(2)
[13] AMIN A R, ATTUR M G, THAKKER G D. A novel mechanism of action of tetracyclines:effects on nitric oxide synthases. 1996(24). doi:10.1073/pnas.93.24.14014
[14] YONG V W, POWER C, FORSYTH P. Metalloproteinases in biology and pathology of the nervous system. 2001(7). doi:10.1038/35081571
[15] GOLUB L M, RAMAMURTHY N, McNAMARA T F. Tetracyclines inhibit tissue collagenase activity.A new mechanism in the treatment of periodontal disease. 1984(6). doi:10.1111/j.1600-0765.1984.tb01334.x
[16] PAEMEN L, MARTENS E, NORGA K. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. 1996(1). doi:10.1016/0006-2952(96)00168-2
[17] RYAN M E, USMAN A, RAMAMURTHY N S. Excessive matrix metalloproteinase activity in diabetes:inhibition by tetracycline analogues with zinc reactivity. 2001(3)
[18] BRUNDULA V, REWCASTLE N B, METZ L M. Targeting leukocyte MMPs and transmigration:minocycline as a potential therapy for multiple sclerosis. 2002(pt 6). doi:10.1093/brain/awf133
[19] KLOPPENBURG M, VERWEIJ C L, MILTENBURG A M. The influence of tetracyclines on T cell activation. 1995(3)
[20] KLOPPENBURG M, BRINKMAN B M, de ROOIJ-DIJK H H. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes, 1996(4)
[21] ZHU S, STAVROVSKAYA I G, DROZDA M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. 2002(6884). doi:10.1038/417074a
[22] WANG J, WEI Q, WANG CY. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. 2004(19). doi:10.1074/jbc.M313629200
[23] WANG X, ZHU S, DROZDA M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington' s disease, 2003(18)
[24] SCARABELLI T M, STEPHANOU A, PASINI E. Minocycline inhibits caspase activation and reactivation,increases the ratio of XIAP to smac/DIABLO,and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. 2004(5)
[25] LIN S, ZHANG Y, DODEL R. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. 2001(1-2). doi:10.1016/S0304-3940(1)02324-2
[26] BONELLI R M, HEUBERGER C, REISECKER F. Minocycline for Huntington's disease:an open label study, 2003(5)
[27] THOMAS M, ASHIZAWA T, JANKOVIC J. Minocycline in Huntington's disease:a pilot study. 2004(6). doi:10.1002/mds.20018
[28] Huntington Study Group. Minocycline safety and tolerability in Huntington disease, 2004(3) |
